Payment overview · 2025
General Payments
$761.74
37 reported records · 11 companies
Healthcare provider profile · identity verified
Yelena Birger, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MANALAPAN, NJ · NPI 1376598136
Verified facts
What the public records show
CMS Open Payments records show Yelena Birger, MD received $761.74 in general payments during 2025 across 37 reported records.
ABBVIE INC. accounted for 42.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Gemtesa, Jardiance, Linzess, Ozempic, Ubrelvy, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 254 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ubrelvy by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $325.27 | 42.7% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $129.01 | 16.9% | 8 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $68.45 | 9.0% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $52.42 | 6.9% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.72 | 5.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.61 | 5.1% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $30.49 | 4.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.30 | 3.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.25 | 2.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $14.12 | 1.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.10 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $761.74 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $145.23 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $131.48 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $129.01 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $129.01 | 8 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $68.45 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $59.24 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $52.42 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $40.72 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.61 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $38.61 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $34.35 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $30.49 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $28.30 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 79 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 62 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 203 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 254 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 139 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
79 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
254 | 44 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
56 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
113 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
203 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
67 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
139 | 21 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 734 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 558 | 96 |
| Atorvastatin Calcium | Atorvastatin Calcium | 502 | 87 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 484 | 84 |
| Metformin Hcl | Metformin Hcl | 406 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 392 | 61 |
| Lidocaine | Lidocaine | 320 | 74 |
| Diclofenac Sodium | Diclofenac Sodium | 306 | 72 |
| Losartan Potassium | Losartan Potassium | 301 | 60 |
| Famotidine | Famotidine | 257 | 57 |
| Ezetimibe | Ezetimibe | 255 | 40 |
| Linzess | Linaclotide | 254 | 44 |
| Vascepa | Icosapent Ethyl | 251 | 38 |
| Gabapentin | Gabapentin | 248 | 38 |
| Carvedilol | Carvedilol | 210 | 28 |
| Furosemide | Furosemide | 205 | 37 |
| Jardiance | Empagliflozin | 203 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 198 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 179 | 42 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 176 | 33 |
| Simvastatin | Simvastatin | 164 | 27 |
| Eliquis | Apixaban | 163 | 20 |
| Omeprazole | Omeprazole | 163 | 41 |
| Nifedipine Er | Nifedipine | 156 | 25 |
| Repaglinide | Repaglinide | 155 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 21 |
| Ozempic | Semaglutide | 139 | 21 |
| Candesartan Cilexetil | Candesartan Cilexetil | 136 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 58 |
| Valsartan | Valsartan | 127 | 28 |
| Tradjenta | Linagliptin | 125 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 121 | 22 |
| Lisinopril | Lisinopril | 121 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 117 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 115 | 34 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 113 | 16 |
| Farxiga | Dapagliflozin Propanediol | 113 | 19 |
| Alendronate Sodium | Alendronate Sodium | 110 | 18 |
| Potassium Chloride | Potassium Chloride | 104 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 104 | 24 |
| Glimepiride | Glimepiride | 102 | 15 |
| Tramadol Hcl | Tramadol Hcl | 98 | 23 |
| Ammonium Lactate | Ammonium Lactate | 92 | 27 |
| Azithromycin | Azithromycin | 92 | 71 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 13 |
| Xarelto | Rivaroxaban | 83 | 11 |
| Meclizine Hcl | Meclizine Hcl | 82 | 32 |
| Memantine Hcl | Memantine Hcl | 81 | 15 |
| Creon | Lipase/Protease/Amylase | 79 | 13 |
| Finasteride | Finasteride | 78 | 13 |
| Meloxicam | Meloxicam | 76 | 31 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 70 | suppressed |
| Januvia | Sitagliptin Phosphate | 68 | 12 |
| Mounjaro | Tirzepatide | 67 | 14 |
| Dexlansoprazole Dr | Dexlansoprazole | 65 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 63 | 24 |
| Sertraline Hcl | Sertraline Hcl | 63 | suppressed |
| Gemtesa | Vibegron | 62 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | suppressed |
| Torsemide | Torsemide | 62 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 45 |
| Clonidine Hcl | Clonidine Hcl | 60 | 20 |
| Cefuroxime | Cefuroxime Axetil | 59 | 41 |
| Irbesartan | Irbesartan | 59 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 58 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 58 | 20 |
| Ranolazine Er | Ranolazine | 58 | suppressed |
| Prolia | Denosumab | 56 | 34 |
| Alprazolam | Alprazolam | 54 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 54 | 13 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 53 | 15 |
| Synthroid | Levothyroxine Sodium | 53 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 52 | 32 |
| Doxazosin Mesylate | Doxazosin Mesylate | 52 | suppressed |
| Eszopiclone | Eszopiclone | 52 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 52 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 51 | 13 |
| Azelastine Hcl | Azelastine Hcl | 48 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | suppressed |
| Myrbetriq | Mirabegron | 46 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 45 | suppressed |
| Trulicity | Dulaglutide | 45 | suppressed |
| Allopurinol | Allopurinol | 44 | suppressed |
| Sucralfate | Sucralfate | 44 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 41 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 23 |
| Loperamide | Loperamide Hcl | 38 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 25 |
| Mupirocin | Mupirocin | 37 | 29 |
| Entresto | Sacubitril/Valsartan | 35 | suppressed |
| Methotrexate | Methotrexate Sodium | 35 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 14 |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 26 |
| Nystatin | Nystatin | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | 13 |
| Atenolol | Atenolol | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Nexium | Esomeprazole Magnesium | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 14 |
| Ketoconazole | Ketoconazole | 32 | 12 |
| Levofloxacin | Levofloxacin | 32 | 28 |
| Rizatriptan | Rizatriptan Benzoate | 31 | suppressed |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 29 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 26 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 26 | suppressed |
| Dexilant | Dexlansoprazole | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Lubiprostone | Lubiprostone | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 19 |
| Valacyclovir | Valacyclovir Hcl | 25 | 17 |
| Febuxostat | Febuxostat | 24 | suppressed |
| Procto-Med Hc | Hydrocortisone | 24 | suppressed |
| Ciclopirox | Ciclopirox | 23 | suppressed |
| Ofloxacin | Ofloxacin | 23 | 18 |
| Spironolactone | Spironolactone | 23 | suppressed |
| Ursodiol | Ursodiol | 23 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 22 | suppressed |
| Crestor | Rosuvastatin Calcium | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Coreg Cr | Carvedilol Phosphate | 21 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Bystolic | Nebivolol Hcl | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Prednisone | Prednisone | 19 | 11 |
| Proctozone-Hc | Hydrocortisone | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Alogliptin | Alogliptin Benzoate | 17 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Telmisartan | Telmisartan | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 15 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Restasis Multidose | Cyclosporine | 14 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 14 | suppressed |
| Ubrelvy | Ubrogepant | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 13 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Plavix | Clopidogrel Bisulfate | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Zegerid | Omeprazole/Sodium Bicarbonate | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Avalide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Ambien | Zolpidem Tartrate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Trospium Chloride | Trospium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $761.74 · 37 records | ABBVIE INC. | AIRSUPRA, CREON, Cologuard Collection Kit, GEMTESA, JARDIANCE, LINZESS, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, VOQUEZNA, YUPELRI, ZENPEP, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error